AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836395 Influenza saRNA
Description: Intramuscular injection
Study NCT05986838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: aser puncture
Description: laser puncture (3 sessions per week)
Study NCT05986838 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultraviolet radiatio
Description: ultraviolet radiation (3 sessions per week)
Study NCT05986838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: for 3 months
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07836396 Influenza saRNA
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07867246 Influenza saRNA
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine (QIV)
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07871987 Influenza saRNA
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07914705 Influenza saRNA
Description: Intramuscular injection
Study NCT05227001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-07915048 Influenza saRNA
Description: Intramuscular injection
Study NCT04760093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low polyphenol concentration extra virgin olive oil (EVOO)
Description: Subjects will complete a consecutive 28-day period of consuming low polyphenol concentration EVOO daily.
Study NCT04760093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High polyphenol concentration extra virgin olive oil (EVOO)
Description: Subjects will complete a consecutive 28-day period of consuming high polyphenol concentration EVOO daily.
Study NCT06304831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality ratings of health care providers for children
Description: Ratings of overall and components of quality (provider knowledge, respectfulness of provider, respectfulness of staff, cleanliness, cost) of health care providers for children will be provided on a webpage. The webpage will be updated every week and participants will be invited to access the latest ratings biweekly.
Study NCT06270966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Remediation
Description: Participants will undergo a 3-months cognitive remediation program using fully immersive VR with two sessions per week. Each session will last a maximum of sixty minutes and will be supervised by expert health professionals. The experimental group participated in an immersive VR-based CR program using the CEREBRUM software designed by clinicians and experts specializing in cognitive rehabilitation.~CEREBRUM provides 52 exercises: Attention, Working Memory, Memory and Learning and Cognitive Estimates. The intervention included 24 sessions.
Study NCT04781374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Oral, once daily with 28 consecutive days defined as a treatment cycle, dosage per protocol ,
Study NCT06543602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: multi-model monitoring and alert
Description: All agitated critically illed patients are monitored by manual and multi-model monitoring and alert system
Study NCT05725590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External pancreatic duct stent
Description: All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The external pancreatic duct stent left the other end exteriorized through the proximal jejunum via a small enterotomy that was fixed in the abdominal wall.
Study NCT05725590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal pancreatic duct stent
Description: All pancreaticoduodenectomies were performed by the same surgical team at our pancreatic center throughout the study period. According to the preoperative laboratory results, medical imaging data, and intraoperative conditions, the laparoscopic or open pancreaticoduodenectomy, or pylorus-preserving pancreaticoduodenectomy was performed at the discretion of the individual surgeon. The child's technique was implemented to achieve digestive tract reconstruction, and all patients underwent a duct-to-mucosa pancreaticojejunostomy. The internal pancreatic duct stent, a silicone catheter with multiple side pores, was inserted into the main pancreatic duct and the other end was placed in the jejunum cavity.
Study NCT05089994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided injection
Description: using 2.5mg/kg of 0.25% bupivacaine diluted in a 20 mL syringe of normal saline , received ultrasound-guided quadratus lumborum.
Study NCT04612738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hello (serious game)
Description: Commercially available, 'Hello' 32 is a serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The creators developed the questions following interviews with palliative care clinicians, hospice nurses, and funeral directors, and then revised them through a series focus groups with >100 patients/caregivers from diverse backgrounds.
Study NCT04612738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Conversation Project (CP) Starter Kit
Description: The CP Starter Kit is one of the most widely promoted and disseminated ACP tools nationwide, is available for free online, and does not require a healthcare professional for use. Like 'Hello', it is intended to help individuals have end-of-life conversations with loved ones. The 11-page workbook has open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so. It also prompts participants to rank priorities on a 5-point scale (e.g., What are your concerns about treatment? 1= I'm worried I won't get enough care, 5= I'm worried I'll get overly aggressive care). The CP website provides resources for running a community event using the 'CP Starter Kit', including a 23-page manual, Coaching the Conversation- A Guide to Facilitating Conversation Groups, with details on hosting a community-based program.
Study NCT04612738 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Table Topics (general conversation game)
Description: Table topics is a popular, commercially available conversation starter game that consists of question cards to prompt conversations (e.g., 'What do you love about your hometown?').
Study NCT06128902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tele health
Description: home based exercise and telenursing
Study NCT05508698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precommitment Nudge
Description: Ask participants to commit to a decision about getting a flu shot
Study NCT05508698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salience
Description: Additional text and icon in the flu shot alert makes the pre-visit questionnaire response salient to the clinician, which could facilitate action or further discussion with the patient
Study NCT06246240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing gum with vitamin C
Description: Will chew vitamin C gum as soon as nausea begins
Study NCT05812157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily dietary supplementation with Fibruline
Description: Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
Study NCT05812157 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily dietary supplementation with Fibruline
Description: Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
Study NCT05812157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-IL-17 therapy
Description: Patients in both groups will be on anti-IL-17 therapy
Study NCT05812157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-IL-17 therapy
Description: Patients in both groups will be on anti-IL-17 therapy
Study NCT04195308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS-DLPFC
Description: Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator.
Study NCT04195308 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study NCT04195308 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Open label TBS-DLPFC
Description: Patients will have the option of receiving active, open label aTBS treatment following sham.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device.
Study NCT06193252 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Increase of physical activity volume and intensity with the use of a motivational smartphone application
Description: A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
Study NCT06193252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increase of physical activity volume and intensity with the use of a motivational smartphone application
Description: A motivational smartphone application will be available for all participants using their own smartphone: the Slow-SPEED app. The Slow-SPEED app will motivate participants to increase the volume and intensity of their physical activity in daily life over a long period of time (2 years) based on their own baseline levels. Different treatment arms will receive different physical activity goals. The app offers participants feedback and support, that will stimulate them to reach their individual physical activity goal (i.e. incremental relative increase of step count and minutes exerting ≥ 64% of maximum heart rate reflecting MVPA relative to baseline level.).
Study NCT04895722 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 400 mg or 200 mg pembrolizumab administered via IV infusion.
Study NCT04895722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg or 200 mg pembrolizumab administered via IV infusion.
Study NCT04895722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Co-formulated pembrolizumab/quavonlimab (400 mg/25 mg) fixed-dose combination (FDC) administered via IV infusion.
Study NCT04895722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Favezelimab
Description: Co-formulated pembrolizumab/favezelimab (200 mg/800 mg) FDC administered via IV infusion
Study NCT04895722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Co-formulated pembrolizumab/vibostolimab (200 mg/200 mg) FDC administered via IV infusion
Study NCT04895722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: 800 mg MK-4830 administered via IV infusion
Study NCT06523673 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.
Study NCT06523673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: second-line systemic therapy
Description: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
Study NCT06523673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: second-line systemic therapy
Description: a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen
Study NCT06167837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide Sulfone
Description: Metoclopramide 10mg+NSS 10 ml IV 30-60 minutes before EGD
Study NCT06167837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 10 mL Injection
Description: Normal saline 10 ml IV 30-60 minutes before EGD
Study NCT06353984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Minimeal product
Description: Intervention product consisting of bioprocessed oats and chickpeas
Study NCT06353984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference product
Description: Reference product mimicking available soups and fruit drinks
Study NCT05416580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA (Ursodeoxycholic acid)
Description: UDCA is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
Study NCT05416580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
Study NCT05416580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
Study NCT05416580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin therapy is administered in the recommended dose in patients with type 2 diabetes mellitus.
Study NCT04496726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacran and Sapnov P quillaja
Description: Cranberry (450 mg) and quillaja (50 mg) capsules taken orally twice daily (morning and evening) for a total daily dose of 900 mg cranberry and 100 mg quillaja for 14 days. Nitrofurantoin 100 mg taken orally twice daily for five days as a rescue medication if symptoms do not subside.
Study NCT04369560 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: 60-cm wide bore 3T scanner (Siemens AG, Erlangen, Germany) with a 32-channel pelvic phased-array coil placed over the bladder.
Study NCT04369560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol intravesical administration (4mM)
Description: A paramagnetic macrocyclic gadolinium-based contrast agent administered intravenously for use in magnetic resonance imaging. Contrast-enhancement is a result of the neutral complex of gadolinium and dihydroxy-hydroxymethylpropyl- tetraazacyclododecane-triacetic acid (butrol).
Study NCT04369560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol intravesical administration (5 mM)
Description: An iron preparation (Fe3O4) approved for intravenous treatment of anemia in the setting of renal failure, comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution.
Study NCT06419322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Optimized rehabilitation program
Description: Consisting of: goal-oriented rehabilitation, hands on physiotherapy sessions and home use of SMA approved rehabilitation device.
Study NCT05358821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: SAGE-718 oral softgel lipid capsules
Study NCT05358821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-718-matching oral capsules
Study NCT05356260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URincontrol4men
Description: The intervention is built as an app
Study NCT05356260 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: CAU will be that typically provided by GPs. Also patients will be informed about a page on thuisarts.nl regarding male LUTS. The pragmatic trial design means that care can vary depending on the preferences of patients and GPs in this group.
Study NCT06338319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book-Sharing for Toddlers with Clefts (BOOST)
Description: BOOST is a dialogic book-sharing intervention. Topics covered include strategies to increase the frequency of shared reading, child engagement and involvement in reading, and strategies to promote language development. Handouts will be shared during the sessions (using the Zoom share screen feature) and sent to families to summarize the content. Parents will record and securely upload shared reading videos during the intervention period. The research team will send prompts for these video uploads after each intervention session. Interventionists will review these videos between sessions to identify parent strengths, application of target skills, and opportunities for improvement.
Study NCT05875181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tFUS
Description: tFUS is a brief stimulation of a part of the brain called the ventral striatum with low-intensity sound waves that pass through the scalp and skull safely.
Study NCT05875181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tFUS
Description: Sham tFUS goes through the motions of applying tFUS to the brain. Participants will know that one session will be a sham, but they will be blinded to which session is the sham
Study NCT06479070 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: A blood sample of 20 mL (2 tubes of 10 mL) for research purposes will be collected during:~* The day of the centering scan (Visit 1);~* During treatment at Week 2 and Week 6 (+/- 1 week) (Visit 2 and 3);~* The day of the post-therapeutic visit scheduled between 3 and 5 weeks after the end of radiotherapy, whether or not associated with concomitant treatment (Visit 4);~* At each monitoring visit following radiotherapy associated or not with concomitant treatment (every 3 months for 24 months (V5 to V12 ; V12 = final visit)~* When the disease progresses before initiation of the 2nd line of treatment.
Study NCT04769037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B. infantis
Description: Activated B. infantis EVC001; Bifidobacterium longum subsp. infantis; 8 x 109 colony forming units (CFU) per day
Study NCT04769037 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose identical in appearance and taste to the active supplement
Study NCT05630183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: A fully human fragment crystallizable-enhanced monoclonal cytotoxic T lymphocyte antigen 4 antibody administered intravenously.
Study NCT05630183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard-of-care chemotherapy administered intravenously.
Study NCT05630183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Standard-of-care chemotherapy administered intravenously.
Study NCT05630183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Standard-of-care chemotherapy administered intravenously.
Study NCT05630183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Standard-of-care chemotherapy administered intravenously.
Study NCT05979441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EFG PH20 SC
Description: Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
Study NCT06118411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets
Study NCT06118411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablets
Study NCT06118411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NB-UVB (narrow-band ultraviolet B) Phototherapy
Description: NB-UVB phototherapy is a commonly used treatment modality in participants with vitiligo and can be administered in an office setting or at home 2 times per week
Study NCT04079621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)